Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Biomark Res. 2013 Feb 5;1(1):10. doi: 10.1186/2050-7771-1-10.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. Currently, surgical resection, liver transplantation, and local ablation are considered curative therapeutic practices for HCC. The diagnosis of HCC without pathologic confirmation is achieved by analyzing serum alpha-fetoprotein (AFP) levels combined with imaging techniques, including ultrasonography, magnetic resonance imaging, and computerized tomography. Although progress has been made in the diagnosis and management of HCC, its prognosis remains dismal. Various new technologies have identified numerous novel biomarkers with potential diagnostic as well as prognostic value, including Dickkopf-1 and Golgi protein 73. These biomarkers not only help in the early diagnosis and prediction of prognosis, but also assist in identifying potential targets for therapeutic interventions. In this article, we provide an up-to-date review of the biomarkers that are used for early diagnosis, prognosis prediction, and personalized treatment of HCC.
肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一。目前，手术切除、肝移植和局部消融被认为是 HCC 的根治性治疗方法。HCC 的诊断未经病理证实，通过分析血清甲胎蛋白（AFP）水平并结合影像学技术，包括超声、磁共振成像和计算机断层扫描来实现。尽管 HCC 的诊断和管理取得了进展，但预后仍然不佳。各种新技术已经确定了许多具有潜在诊断和预后价值的新型生物标志物，包括 Dickkopf-1 和高尔基糖蛋白 73。这些生物标志物不仅有助于早期诊断和预测预后，还有助于确定治疗干预的潜在靶点。本文就用于 HCC 的早期诊断、预后预测和个体化治疗的生物标志物进行了综述。
